Initiate At Buy: Harnessing Natural Killer Cell Biology To Tackle AID

研报英文原文证据摘录

Initiate At Buy: Harnessing Natural Killer Cell Biology To Tackle AID

TD Cowen Nkarta Therapeutics

Global Research June 23, 2026

Bringing NK Cell Therapy To Autoimmune Disease

Autoimmune disease is increasingly emerging as a compelling next frontier for cell

therapy, driven by the growing recognition that many severe, refractory indications

are fundamentally mediated by pathogenic B cells and remain inadequately

addressed by current standards of care. Despite affecting ~7 million patients in the

U.S., treatment today is largely centered around chronic, outpatient

immunosuppression that rarely induces durable remission and is often constrained

by cumulative toxicity. Encouragingly, recent results with CD19-directed cell

therapies from academia and companies have begun to challenge this paradigm,

showing that a one-time B-cell-depleting intervention can drive deep, drug-free

remissions lasting multiple years across diseases including lupus, myositis and

systemic sclerosis. Mechanistically, transient depletion of autoreactive B cells

followed by reconstitution with naïve populations may enable a functional "immune

reset," offering the potential to alter disease course rather than simply manage

symptoms. Taken together, these data have catalyzed significant interest in applying

cell therapy to autoimmune disease and support a shift toward potentially curative,

one-time treatment approaches.

NKX019: CD19 CAR NK Cell Therapy For Autoimmune Disorders

Source: Nkarta Therapeutics

The NK Platform: A New Take On Cell Therapies

Nkarta’s NK Platform Holds Several Advantages Over Other Cellular Therapies

The cell therapy space has been historically dominated by the CAR T modality,

engineered to have specificity for CD19 expressed on B-cells. The first generation of